Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy

Journal of Rheumatology

Volumn 32, Issue 4, 2005, Pages 609-615

  Mo, Yin Mok ^a,b   Lo, Yi ^b   Tak, Mao Chan ^a   Woon, Sing Wong ^b   Chak, Sing Lau ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Chemoprophylaxis; Corticosteroid; Mycobacterial infection; Systemic lupus erythematosus; Tuberculosis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ISONIAZID; PREDNISOLONE; PYRIDOXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG MEGADOSE; ENDEMIC DISEASE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INFECTION SENSITIVITY; LUNG TUBERCULOSIS; MALE; MEDICAL RECORD; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTITUBERCULAR AGENTS; AZATHIOPRINE; ENDEMIC DISEASES; FEMALE; GLUCOCORTICOIDS; HONG KONG; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; ISONIAZID; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREDNISOLONE; RECURRENCE; TUBERCULOSIS;

EID: 17144415925     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Baughman RP. The lung in the immunocompromised patient. Infectious complications. Part 1. Respiration 1999;66:95-109.
2. Casado JL, Moreno S, Fortun J, et al. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients. Clin Infect Dis 2002;34:386-9.
3. Hall CM, Wilcox PA, Swanepoel CR, Kahn D, Van Zyl Smit R. Mycobacterial infection in renal transplant patient. Nephron 1980;26:187-8.
4. Qunibi WY, Al-Sibai MD, Taher S, et al. Mycobacterial infection after renal transplantation - report of 14 cases and review of the literature. QJM 1990;282:1039-60.
5. Riminton S, Pearce N, Antony B. Tuberculosis and treatment with infliximab. New Engl J Med 2002;346:623-6.
6. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. New Engl J Med 2001;345:1098-104.
7. De Pinho AM, Santoro-Lopes G, Harrison LH, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS 2001;15:2129-35.
8. Porter JDH, McAdam KPWJ. Tuberculosis in Africa in the AIDS era: the role of chemoprophylaxis. Trans R Soc Trop Med Hyg 1992;86:467-9.
9. International Union Against Tuberculosis. Efficacy of various duration of isoniazid preventive therapy for tuberculosis: Five Years of Follow-up IUAT Trial. Bull WHO 1982;60:555-64.
10. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD Jr, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000;356:1470-4.
11. Centers for Disease Control and Prevention. The use of preventive therapy for tuberculous infection in the United States: Recommendations for the Advisory Committee for the Elimination of Tuberculosis. Morb Mortal Wkly Rep 1990;39:9-12.
12. Terry Beim Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trial Group, the PAN American Health Organisation and the Centers for Disease Control and Prevent Study Group. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 200;283:1445-50.
13. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-74.
14. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-58.
15. Israel HL, Gottlieb JE, Maddrey WC. Perspectives: Prevention isoniazid therapy and the liver. Chest 1992;101:1298-31.
16. Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: A review of available information. Am Rev Respir Dis 1992;145:494-7.
17. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
18. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet 1995;345:1545-9.
19. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
20. Chang KC, Leung CC, Tam CM. Recent trend of tuberculosis in Hong Kong. Pub Health Epidemiol Bull 2002;11:69-75.
21. Hernandez-Cruz B, Sifuentes-Osornio J, Ponce-de-leon-Rosales S, Ponce-de-Leon-Garduno A, Diaz-Jouanen E. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series. Clin Exp Rheumatol 1999;17:289-96.
22. Balakrishnan C, Mangat G, Mittal G, Joshi VR. Tuberculosis in patients with systemic lupus erythematosus. J Assoc Physicians India 1998;46:682-3.
23. Feng PH, Tan TH. Tuberculosis in patients with systemic lupus erythematosus. Ann Rheum Dis 1982;41:11-4.
24. Raj SM, Hunt J. Systemic lupus erythematosus and miliary tuberculosis in a prepubertal girl - a case report. Med J Malaysia 1990;45:347-8.
25. Rovensky J, Kovalancik M, Kristufek P, et al. Contribution to the problem of occurrence of tuberculosis in patients with systemic lupus erythematosus. Z Rheumatol 1996;55:180-7.
26. Victorio-Navarra ST, Dy EE, Arroyo CG, Torralba TP. Tuberculosis among Filipino patients with systemic lupus erythematosus. Semin Arthritis Rheum 1996;26:628-34.
27. Paton NI. Infections in systemic lupus erythematosus patients. Ann Acad Med Singapore 1997;26:694-700.
28. Kim HA, Yoo CD, Baek HJ, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998;16:9-13.
29. Coutts II, Jegarajah S, Stark JE. Tuberculosis in renal transplant recipients. Br J Dis Chest 1979;73:141-8.
30. Neff TA, Hudgel DW. Miliary tuberculosis in a renal transplant recipient. Am Rev Respir Dis 1973;108:677-8.
31. Andonopoulos AP, Safridi C, Karokis D, Bounas A. Is a purified protein derivative skin test and subsequent antituberculous chemoprophylaxis really necessary in systemic rheumatic disease patients receiving corticosteroid? Clin Rheumatol 1998;17:181-5.
32. Higgins RM, Cahn AP, Porter D, et al. Mycobacterial infection after renal transplantation. QJM 1992;286:145-53.
33. John GT, Thomas PP, Thomas M, Jeyaseelan L, Jacob CK, Shastry JCM. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. Transplantation 1994;87:1683-4.
34. Apaydin S, Altiparmak MR, Serdengecti K, Ataman R, Ozturk R, Erek E. Mycobacterium tuberculosis infections after renal transplantation. Scand J Infect Dis 2000;32:501-5.
35. Singh N, Wagener MM, Gayowski T. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation 2002;74:892-5.
36. Hernandez-Cruz B, Ponce-de-leon-Rosales S, Sifuentes-Osornio J, Ponce-de-Leon-Garduno A, Diaz-Jouanen E. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic disease. A case control study. Clin Exp Rheumatol 1999;17:81-7.
37. Gaitonade S, Pathan E, Sule A, Mittal G, Joshi VR. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 2002;61:251-3.